Common Contracts
2 similar Development and License Agreement contracts by Alkermes Plc.
EX-10.3 3 alks-20180331ex10345098f.htm EX-10.3 Execution Version A complete version of this Exhibit has been filed separately with the Securities and Exchange Commission pursuant to an application requesting confidential treatment pursuant to Rule...Development and License Agreement • May 5th, 2020 • Delaware
THIS THIRD AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENT (the “Third Amendment”) is entered into effective as of March 20, 2018, (the “Third Amendment Effective Date”) between AMYLIN PHARMACEUTICALS, LLC, a Delaware limited liability corporation having a principal place of business at 9360 Towne Centre Drive, San Diego, CA 92121 (“Amylin”), and ALKERMES PHARMA IRELAND LIMITED, a private limited company incorporated in Ireland (registered number 448848) having a registered address at Connaught House, 1 Burlington Road, Dublin 4, Ireland (“APIL”) who is the successor-in-interest to ALKERMES CONTROLLED THERAPEUTICS INC. II (“ACTII”). Amylin and APIL are referred to herein collectively as “Parties” and individually as a “Party”.
THIRD AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • April 26th, 2018 • Alkermes Plc. • Pharmaceutical preparations • Delaware
THIS THIRD AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENT (the “Third Amendment”) is entered into effective as of March 20, 2018, (the “Third Amendment Effective Date”) between AMYLIN PHARMACEUTICALS, LLC, a Delaware limited liability corporation having a principal place of business at 9360 Towne Centre Drive, San Diego, CA 92121 (“Amylin”), and ALKERMES PHARMA IRELAND LIMITED, a private limited company incorporated in Ireland (registered number 448848) having a registered address at Connaught House, 1 Burlington Road, Dublin 4, Ireland (“APIL”) who is the successor-in-interest to ALKERMES CONTROLLED THERAPEUTICS INC. II (“ACTII”). Amylin and APIL are referred to herein collectively as “Parties” and individually as a “Party”.
